NCT07303257

Brief Summary

Glaucoma surgery currently relies on a wide therapeutic arsenal, ranging from conventional filtering surgeries to minimally invasive glaucoma surgery (MIGS). These techniques offer distinct efficacy and safety profiles, allowing tailored management across a broad spectrum of patients. Traditionally, surgical success has been evaluated using objective clinical outcomes, such as intraocular pressure (IOP) reduction and decreased reliance on topical treatments. However, the shift toward patient-centered medicine now requires consideration of the patient's perspective, including their subjective experience and the impact of treatment on quality of life. In this context, quality-of-life assessment has become a key component, promoting therapeutic alliance and patient adherence to care pathways. Despite its importance, few studies have evaluated and compared quality of life after glaucoma surgery using comparable surgical techniques. Furthermore, to our knowledge, no study has specifically assessed the independent effect of postoperative follow-up on quality of life after filtering surgery with a bleb. Given that postoperative management can be prolonged and demanding, it may significantly influence patients' perceptions of surgical outcomes and overall well-being. This study aims to address these gaps by providing a more comprehensive evaluation of the impact of glaucoma surgery beyond traditional clinical outcomes. It may represent a first step toward the development of a more appropriate assessment tool that incorporates the realities of postoperative follow-up and the specific experiences of patients undergoing filtering surgery. The study is based on the following hypotheses: filtering glaucoma surgery preserves patients' quality of life, with a stable NEI VFQ-25 score at six months postoperatively; postoperative quality of life may be influenced by the patient's postoperative care pathway; and quality-of-life scores remain correlated with objective clinical parameters, including intraocular pressure, visual acuity, medical treatment burden, and visual field damage.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
132

participants targeted

Target at P50-P75 for all trials

Timeline
15mo left

Started Feb 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress14%
Feb 2026Aug 2027

First Submitted

Initial submission to the registry

December 11, 2025

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 24, 2025

Completed
2 months until next milestone

Study Start

First participant enrolled

February 23, 2026

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2027

Last Updated

March 16, 2026

Status Verified

February 1, 2026

Enrollment Period

1.4 years

First QC Date

December 11, 2025

Last Update Submit

March 12, 2026

Conditions

Keywords

GlaucomaTrabeculectomySclerectomyPreserFlo® Micro ShuntQuality of lifeGlaucome SurgeryMIGSNEI-VFQ 25 (National Eye Institute- Visual Function Questionnaire 25)

Outcome Measures

Primary Outcomes (1)

  • Quality of life score from the NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire-25).

    To evaluate, in adult patients undergoing glaucoma surgery, the change in NEI-VFQ 25 quality of life score between the pre-operative period and 6ᵉ months post-operatively, regardless of the surgical technique used.

    Pre-operative period and 6 months after intervention

Secondary Outcomes (5)

  • Comparison of NEI-VFQ-25 scores between surgical techniques

    6 months postoperatively (M6)

  • Correlation between NEI-VFQ-25 score and postoperative clinical parameters

    Postoperative visits at Month 3 (M3)

  • Correlation between NEI-VFQ-25 score and postoperative clinical parameters

    Postoperative visits at Month 6 (M6)

  • Impact of postoperative follow-up on NEI-VFQ-25 quality-of-life scores at 3 months

    Prospective collection of postoperative follow-up data through Month 3 (M3)

  • Impact of postoperative follow-up on NEI-VFQ-25 quality-of-life scores at 6 months

    Prospective collection of postoperative follow-up data through Month 6 (M6)

Study Arms (1)

Adult with open-angle/angle-closure or exfoliative or pigmentary glaucoma and a surgical indication

Adult patient with different stage of glaucoma and a surgical indication for sclerectomy + Mitomycin, PRESERFLO + Mitomycin, or trabeculectomy + Mitomycin. .

Other: NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire-25).

Interventions

The NEI-VFQ-25 questionnaire, translated into French and validated by the French National Authority for Health (HAS), is used to assess quality of life related to visual function. This questionnaire includes 25 items divided into 11 subdomains assessing vision-related functioning and 1 subdomain assessing general health status (see appendix for the detailed list). The composite score ranges from 0 to 100, with lower scores indicating a poorer perceived level of health and visual functioning.

Adult with open-angle/angle-closure or exfoliative or pigmentary glaucoma and a surgical indication

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Glaucoma patients aged ≥ 18 years, operated on using one of the following 3 types of surgery: Trabeculectomy , Deep non-perforating sclerectomy or Preserflo

You may qualify if:

  • Patient aged ≥ 18 years with an indication for glaucoma surgical treatment
  • Eligible surgical procedures: Preserflo™ MicroShunt with mitomycin C, Trabeculectomy with mitomycin C or non-penetrating deep sclerectomy with mitomycin C
  • Unilateral or bilateral glaucoma, open-angle or angle-closure, at early, moderate, or advanced stages
  • Pseudoxexfoliative or pigmentary glaucoma
  • Secondary glaucoma, including: uveitic glaucoma, Steroid-induced glaucoma, traumatic glaucoma
  • Written informed consent obtained prior to study participation

You may not qualify if:

  • Congenital glaucoma
  • Refractory glaucoma with a history of multiple previous surgeries
  • Severe visual co-morbidities (age-related macular degeneration, severe diabetic retinopathy, retinal degeneration, or similar conditions)
  • Expected difficulty with follow-up including poor anticipated compliance, planned travel or prolonged absence during the follow-up period
  • Illiteracy, inability to speak French or impaired cognitive capacity preventing adequate understanding of the study
  • Patients with a significant pre-existing impairment in quality of life attributable to a progressive physical illness or a neuropsychiatric disorder.
  • Patients under curatorship or guardianship
  • Pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service d'Ophtalmologie, Hôpital de La Croix Rousse, Hospices Civils de Lyon

Lyon, 69317, France

RECRUITING

MeSH Terms

Conditions

Glaucoma, Open-AngleGlaucoma, Angle-ClosureGlaucoma

Condition Hierarchy (Ancestors)

Ocular HypertensionEye Diseases

Central Study Contacts

Victor VERMOT-DESROCHES, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 11, 2025

First Posted

December 24, 2025

Study Start

February 23, 2026

Primary Completion (Estimated)

August 1, 2027

Study Completion (Estimated)

August 1, 2027

Last Updated

March 16, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations